India AI in Healthcare Market Size, Share & Forecast, By Solution Type, Application & End User, 2026–2031

The India AI in Healthcare Market was worth USD 1,331 million in 2025. The estimate covers revenue from software platforms, AI-enabled medical devices, implementation services and managed AI operations sold into hospitals, diagnostics, pharmaceutical companies, payers and public-health programs. Software is the largest solution pool because it scales across imaging, documentation and analytics workflows, while services remain necessary for integration and validation. The value is anchored to a broad country-level market benchmark and reconciled against deployment volumes and enterprise contract economics.

The market is forecast to reach USD 10,772 million by 2031, expanding at a CAGR of 41.70% during 2026-2031. The projection assumes sustained growth in medical imaging, clinical decision support, remote monitoring, drug-development analytics and administrative automation. It also assumes that ABDM interoperability, cloud infrastructure and regulated deployment pathways progressively shorten implementation cycles. The forecast does not require every pilot to convert; it depends on large hospital groups, diagnostic networks, pharma companies and public programs shifting toward multi-year portfolio procurement.

Profit pools will shift from one-time implementation and stand-alone algorithms toward recurring subscriptions, per-study diagnostic fees, managed model operations and outcome-linked enterprise contracts. Software platforms should retain the largest revenue pool, but services can protect margins by embedding integration, clinical validation, cybersecurity and monitoring into long-term agreements. Application economics will favor imaging, clinical documentation, revenue-cycle workflows and remote monitoring because buyers can quantify turnaround time, workforce productivity and avoidable utilization. Vendors offering only model access will face price compression as cloud and open-model capabilities become more accessible.

The primary risk is slow conversion from technically successful pilots into compliant, integrated and paid enterprise deployments. Hospitals operate heterogeneous systems, require clinician acceptance and must address privacy, cybersecurity, device classification and post-market monitoring. Procurement teams also need clear accountability when AI informs diagnosis or treatment. These factors can extend sales cycles and increase implementation cost, particularly for smaller vendors. The risk is manageable for companies that build evidence generation, regulatory strategy, interoperability and change management into the product from the beginning rather than adding them after algorithm development.

India ranks third by 2025 market size among the selected peers, behind China and Japan and ahead of South Korea and Singapore. Its current revenue base is smaller than China’s USD 2,829 million and Japan’s USD 1,658 million, but India’s forecast CAGR of 41.7% is higher than the modeled growth rates for both countries. India’s differentiators are population scale, a rapidly expanding national health-data infrastructure and strong diagnostic-AI entrepreneurship. Its constraint is lower spending per provider and more fragmented implementation across public and private health systems.

The strongest demand factor is the combination of rapidly digitizing health records and persistent clinical capacity pressure. More than 100 crore records were linked to ABHA by May 2026, while India’s doctor-population ratio was estimated at 1:811 in 2025. This creates a commercial need for AI that reduces reporting time, identifies high-risk patients, supports remote monitoring and automates documentation. Adoption will be strongest where buyers can link these capabilities to faster throughput, improved continuity of care, lower denial rates or earlier clinical intervention rather than broad innovation objectives.